TABLE 1

Characteristics of subjects


Subject No.

Sex

Weight

BMI

CYP2C8 Genotype

Trimethoprim Cmax

Trimethoprim AUC0–13 h
kg kg/m2 μg/ml mg · h/l
1 F 65 23 *1/*1 3.6 37.4
2 M 58 18 *1/*1 4.2 38.0
3 M 75 21 *1/*1 2.5 22.2
4 F 72 25 *1/*1 3.3 29.7
5 M 93 27 *1/*1 1.2 7.8
6 F 63 21 *1/*1 3.2 27.9
7 M 76 21 *1/*1 2.2 20.4
8 F 56 21 *1/*1 4.1 36.8
Mean ± S.D. 70 ± 12 22 ± 3 3.0 ± 1.0 27.5 ± 10.5
9 F 60 23 *1/*3 3.3 26.4
10 M 83 23 *1/*3 2.3 22.4
11 M 70 20 *1/*3 2.9 26.2
12 M 62 22 *1/*3 3.0 29.0
13 F 62 19 *1/*3 4.5 41.9
Mean ± S.D. 67 ± 10 22 ± 2 3.2 ± 0.8 29.2 ± 7.5
14 F 69 23 *3/*3 3.0 27.8
15 F 44 18 *3/*3 4.7 41.7
16 M 79 25 *3/*3 2.3 21.3
Mean ± S.D.

64 ± 18
22 ± 4

3.3 ± 1.2
30.3 ± 10.4
  • F, female; M, male; BMI, body mass index; Cmax, peak plasma concentration; AUC0–13 h, area under the plasma concentration-time curve from time 0 to 13 h after the morning dose of trimethoprim on day 3